CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

Communiqués Cannabis Bioscience International Holdings, Inc.

Actions

CBIH

US16948K1060

Recherche biotechnologique et médicale

Temps Différé OTC Markets 20:43:29 28/09/2026			Varia. 5j.	Varia. 1 janv.
0,000200 ^USD	+100,00 %		+33,33 %	-60,00 %

15/07	Cannabis Bioscience International Holdings obtient une licence au Texas pour des produits à base de chanvre consommables	CI
16/04	Cannabis Bioscience International Holdings, Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 28 février 2026	CI

Communiqués

20/07	CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research	NE
15/07	Years of Preparation. One Regulatory Approval. Commercial Launch Begins: CBIH Receives Texas License for Consumable Hemp Products	NE
06/07	CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings	NE
22/06	Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement	NE
15/06	CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research	NE
08/06	CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers	NE
01/06	CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation	NE
19/02	Cannabis Bioscience International : Quarterly Report for Quarter Ending November 30, 2025 (Form 10-Q)	PU
21/01	CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio	NE
12/01	CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence	NE
05/01	CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition	NE
29/12	CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways	NE
22/12	CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities	NE
15/12	CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline	NE
22/10/25	Cannabis Bioscience International : Quarterly Report for Quarter Ending August 31, 2025 (Form 10-Q)	PU
13/10/25	CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery	NE
06/10/25	Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook	NE
29/09/25	CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center	NE
23/09/25	Cannabis Bioscience International : Annual Report for Fiscal Year Ending May 31, 2025 (Form 10-K)	PU
13/01/25	Cannabis Bioscience International : Late Filing Notice (Form NT 10-Q)	PU
13/01/25	Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification	AQ
06/01/25	Cannabis Bioscience International Holdings (CBIH) Announces Partnership with Stephen Gould for Manufacturing and Distribution of Medical Products	AQ
16/12/24	CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing	AQ
09/12/24	A Letter from the Desk of CBIH	AQ
02/12/24	CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hearing	AQ